Thank you for Subscribing to Life Science Review Weekly Brief
Craig Lipset, a pioneer in decentralized clinical trials and an industry innovator, joins the MedVector board of directors and executive advisory board.
FREMONT, CA: Craig Lipset, a pioneer, and leader in the clinical trials industry, joins the MedVector team as a board member and executive advisor.
MedVector's ground-breaking Prime-Control Technology platform enables access to millions of potential clinical trial participants seen daily by physicians who are not interested in becoming study investigators. As a result, the company allows sponsors, clinical research organizations (CROs), and study recruiters to complete studies more quickly and reach a broader patient population from the comfort of their trusted neighborhood doctor's office.
Lipset's strategic role as an executive advisor includes providing insights and strategy to help the MedVector platform realize its full potential by integrating and complementing existing clinical trial processes and market solutions. He will also serve on the board of directors of MedVector and facilitate strategic collaborations with CROs, pharmaceutical companies, clinical trial sites, and patient recruitment leaders.
“MedVector is the first platform that addresses the misaligned incentives that stand in the way of physicians talking to their patients about clinical trials,” says Lipset. “Clinical trial candidates are not medical mysteries. These patients typically have an existing diagnosis, they are on an existing therapy, and they value their trusted relationship with an existing local doctor. Enabling these non-investigator physicians to have access to clinical trials as a care option is the 'holy grail’ of participant enrollment, and MedVector is doing just that.”
Founder and CEO Scott Stout. “His reputation and track record in the pharma and clinical trials arena will help propel us forward as we partner with CROs to increase enrollment.”
Craig Lipset is the Decentralized Trials & Research Alliance (DTRA) co-chair, the world's largest not-for-profit organization dedicated to accelerating the global adoption of decentralized research. The FDA, leading pharmaceutical companies, technology, service providers, and other healthcare organizations are among the more than 100 members of this growing collaborative.
Lipset advises major pharmaceutical companies on clinical innovation and is an adjunct assistant professor of health informatics at Rutgers University.
Before co-founding DTRA, Craig served as head of clinical innovation and venture partner at Pfizer, as a member of theTransCelerate Biopharma founding operations committee, and as a member of the founding management teams of two successful startups ventures, Perceptive Informatics and Adnexus Therapeutics.